Prognostic Significance of Overexpression of EZH2 and H3k27me3 Proteins in Gastric Cancer |
He, Long-Jun
(The State Key Laboratory of Oncology in South China)
Cai, Mu-Yan (The State Key Laboratory of Oncology in South China) Xu, Guo-Liang (The State Key Laboratory of Oncology in South China) Li, Jian-Jun (The State Key Laboratory of Oncology in South China) Weng, Zi-Jin (Department of Gastroenterology, the First Affiliated Hospital, Sun Yat-sen University) Xu, Da-Zhi (The State Key Laboratory of Oncology in South China) Luo, Guang-Yu (The State Key Laboratory of Oncology in South China) Zhu, Sen-Lin (Department of Pathology, the Third Affiliated Hospital, Sun Yat-sen University) Xie, Dan (The State Key Laboratory of Oncology in South China) |
1 | Rao ZY , Cai MY , Yang GF, et al (2010). EZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-beta1 and is a predictor of outcome in ovarian carcinoma patients. Carcinogenesis, 31, 1576-83. DOI ScienceOn |
2 | Schlesinger Y, Straussman R, Keshet I, et al (2007). Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat Genet, 39, 232-6. DOI |
3 | Strahl BD, Allis CD (2000). The language of covalent histone modifications. Nature, 403, 41-5. DOI ScienceOn |
4 | Tonini T, D'Andrilli G, Fucito A, Gaspa L, Bagella L (2008). Importance of Ezh2 polycomb protein in tumorigenesis process interfering with the pathway of growth suppressive key elements. J Cell Physiol, 214, 295-300. DOI |
5 | Tzao C, Tung HJ, Jin JS, et al (2009). Prognostic significance of global histone modifications in resected squamous cell carcinoma of the esophagus. Mod Pathol, 22, 252-60. DOI |
6 | Weikert S, Christoph F, Kollermann J, et al (2005). Expression levels of the EZH2 polycomb transcriptional repressor correlate with aggressiveness and invasive potential of bladder carcinomas. Int J Mol Med, 16, 349-53. |
7 | Wei Y, Xia W, Zhang Z, et al (2008). Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers. Mol Carcinog, 47, 701-6. DOI |
8 | Widschwendter M, Fiegl H, Egle D, et al (2007). Epigenetic stem cell signature in cancer. Nat Genet, 39, 157-8. DOI |
9 | Yasui W, Yokozaki H, Fujimoto J, et al (2000). Genetic and epigenetic alterations in multistep carcinogenesis of the stomach. J Gastroenterol, 35, 111-5. |
10 | Yasui W, Oue N, Kuniyasu H, et al (2001). Molecular diagnosis of gastric cancer: present and future. Gastric Cancer, 4, 113-21. DOI |
11 | Yonemitsu Y, Imazeki F, Chiba T, et al (2009). Distinct expression of polycomb group proteins EZH2 and BMI1 in hepatocellular carcinoma. Hum Pathol, 40, 1304-11. DOI |
12 | Yu J, Yu J, Rhodes DR, et al (2007). A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. Cancer Res, 67, 10657-63. DOI |
13 | Cai MY, Tong ZT, Zheng F, et al (2011). EZH2 protein: a promising immunomarker for the detection of hepatocellular carcinomas in liver needle biopsies. Gut, 60, 967-76. DOI |
14 | Bachmann IM, Halvorsen OJ, Collett K, et al (2006). EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol, 24, 268-73. |
15 | Bryant RJ, Cross NA, Eaton CL, Hamdy FC, Cunliffe VT (2007). EZH2 promotes proliferation and invasiveness of prostate cancer cells. Prostate, 67, 547-56. DOI |
16 | Cai MY, Hou JH, Rao HL, et al (2011). High expression of H3K27me3 in human hepatocellular carcinomas correlates closely with vascular invasion and predicts worse prognosis in patients. Mol Med, 17, 12-20. |
17 | Cai MY, Tong ZT, Zhu W, et al (2011). H3K27me3 protein is a promising predictive biomarker of patients' survival and chemoradioresistance in human nasopharyngeal carcinoma. Mol Med, 17, 1137-45. |
18 | Cao R, Wang L, Wang H, et al (2002). Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science, 298, 1039-43. DOI ScienceOn |
19 | Esteller M (2008). Epigenetics in cancer. N Engl J Med, 358, 1148-59. DOI ScienceOn |
20 | Collett K, Eide GE, Arnes J, et al (2006). Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer. Clin Cancer Res, 12, 1168-74. DOI |
21 | Green D, de Leon S P, Leon-Rodriguez E, Sosa-Sanchez R (2000). Adenocarcinoma of the stomach: univariate and multivariate analysis of factors associated with survival. Am J Clin Oncol, 25, 84-9. |
22 | Harrison LE, Karpeh MS, Brennan MF (1998). Extended lymphadenectomy is associated with a survival benefit for node-negative gastric cancer. J Gastrointest Surg, 2, 126-31. DOI |
23 | He LR, Liu MZ, Li BK, et al (2009). Prognostic impact of H3K27me3 expression on locoregional progression after chemoradiotherapy in esophageal squamous cell carcinoma. BMC Cancer, 9, 461. DOI |
24 | He LR, Liu MZ, Li BK, et al (2010). High expression of EZH2 is associated with tumor aggressiveness and poor prognosis in patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy. Int J Cancer, 127, 138-47. DOI |
25 | Maruyama K, Sasako M, Kinoshita T (1992). Wert der systematischen erweiterten Lymphknotendissektion--Ergebnisse in Japan. [Value of systematic extended lymph node dissection--results in Japan]. Langenbecks Arch Chir Suppl Kongressbd, 1992, 130-5. |
26 | Matsukawa Y, Semba S, Kato H, et al (2006). Expression of the enhancer of zeste homolog 2 is correlated with poor prognosis in human gastric cancer. Cancer Sci, 97, 484-91. DOI |
27 | Msika S, Benhamiche AM, Jouve JL, Rat P, Faivre J (2000). Prognostic factors after curative resection for gastric cancer. A population-based study. Eur J Cancer, 36, 390-6. DOI ScienceOn |